Topics

Stage IV NSCLC and New Targets: RET

13:06 EDT 12 Sep 2019 | GRACE
H. Jack West, MD, Founder, President and CEO

We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services at City of Hope Comprehensive Cancer Center, and Founder, President and CEO Of GRACE, Charu Aggarwal, MD, MPH with the Perelman Center for Advanced Medicine, University of Pennsylvania, and Benjamin Levy MD, Clinical Director Of Medical Oncology, Assistant Professor Of Oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.

The doctors recently collaborated from their respective geographical locations to review top discussion points from Lung Cancer from ASCO 2019.  In this video, the doctors discuss stage 4 non-small cell lung cancer and new targets, specifically RET. 

Please visit our community forums with any questions or comments! 

 

 

Video Language: 

Original Article: Stage IV NSCLC and New Targets: RET

NEXT ARTICLE

More From BioPortfolio on "Stage IV NSCLC and New Targets: RET"

Quick Search

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...